Vivek Subbiah: Privileged to collaborate with SCRI pillars Lisa Morrissey and Suzanne Jones

Vivek Subbiah shared a post on LinkedIn:

“Privileged to collaborate with SCRI pillars Lisa Morrissey and Suzanne Jones, each contributing decades of invaluable experience at Sarah Cannon Research Institute
Their wealth of wisdom and resilience in overcoming roadblocks is truly inspiring, ensuring successful delivery of clinical trials across communities”.

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.